Tarceva and Renal impairment - a phase IV clinical study of FDA data

Summary:

Renal impairment is reported as a side effect among people who take Tarceva (erlotinib hydrochloride), especially for people who are male, 60+ old, have been taking the drug for < 1 month also take Avastin, and have Lung neoplasm malignant.

The phase IV clinical study analyzes which people have Renal impairment when taking Tarceva. It is created by eHealthMe based on reports of 30,795 people who have side effects when taking Tarceva from the FDA, and is updated regularly.

What is Tarceva?

Tarceva has active ingredients of erlotinib hydrochloride. It is often used in lung cancer. eHealthMe is studying from 31,036 Tarceva users. Check the latest studies of Tarceva.

What is Renal impairment?

Renal impairment (severely reduced kidney function) is found to be associated with 2,209 drugs and 2,470 conditions by eHealthMe. Check the latest studies of Renal impairment.

On Jul, 13, 2026

30,795 people reported to have side effects when taking Tarceva.
Among them, 56 people (0.18%) have Renal impairment.

Among these 56 people:

How long have people been on Tarceva when they have Renal impairment? *

What is the gender of people who have Renal impairment when taking Tarceva? *

female: 39.62 %
male: 60.38 %

What is the age of people who have Renal impairment when taking Tarceva? *

What are other drugs people take besides Tarceva? *

What are other side effects people have besides Renal impairment? *

Rashes (redness): 11 people, 19.64%
Diarrhea: 9 people, 16.07%
Appetite - Decreased (decreased appetite occurs when you have a reduced desire to eat): 7 people, 12.50%
Anaemia (lack of blood): 6 people, 10.71%
White Blood Cell Count Decreased: 5 people, 8.93%
Blood Bilirubin Increased: 5 people, 8.93%
Malignant Neoplasm Progression (cancer tumour came back): 5 people, 8.93%
Constipation: 5 people, 8.93%
Hepatic Function Abnormal: 5 people, 8.93%
Arrhythmias (irregular heartbeat): 4 people, 7.14%

What are the existing conditions these people have? *

Lung Neoplasm Malignant (cancer tumour of lung): 17 people, 30.36%
Lung Adenocarcinoma (a form of non-small cell lung cancer): 8 people, 14.29%
Metastases To Bone (cancer spreads to bone): 4 people, 7.14%
Constipation: 4 people, 7.14%
Diabetes: 4 people, 7.14%
Non-Small Cell Lung Cancer Metastatic (type of epithelial lung cancer spreads to other parts): 4 people, 7.14%
Gout (uric acid crystals building up in the body): 3 people, 5.36%
Gastritis (inflammation of stomach): 2 people, 3.57%
Insomnia (sleeplessness): 2 people, 3.57%
Hypothyroidism (abnormally low activity of the thyroid gland, resulting in retardation of growth and mental development): 2 people, 3.57%

* Approximation only. Some reports may have incomplete information.

Do you take Tarceva and have Renal impairment?

- Check whether Renal impairment is associated with a drug or a condition
- Predict drug outcomes for up to one year with AI
- Get an AI agent to monitor your drugs continuously

Related studies:

Effectiveness of, long term effects of, and alternative drugs to Tarceva:

Tarceva (31,036 reports)

Renal impairment treatments and more:

Renal impairment (99,633 reports)

Browse all side effects of Tarceva:

a b c d e f g h i j k l m n o p q r s t u v w x y z

Browse all the drugs that are associated with Renal impairment:

Renal impairment (2,209 drugs)

Browse all the conditions that are associated with Renal impairment:

Renal impairment (2,470 conditions)

Related publications that referenced our studies

Al-Hamdy RA, "Assessment of electrolytes and HbA1c in type 2 diabetic patients using metformin and evaluation of guidelines obedience regarding renal impairment", J.Thi-Qar Sci., 2015 Jan .
Al-Hamdy RA, "Assessment of electrolytes and HbA1c in type 2 diabetic patients using metformin and evaluation of guidelines obedience regarding renal impairment", J.Thi-Qar Sci., 2015 Jan .

How the study uses the data?

The study uses data from the FDA. It is based on erlotinib hydrochloride (the active ingredients of Tarceva) and Tarceva (the brand name). Other drugs that have the same active ingredients (e.g. generic drugs) are not considered. Dosage of drugs is not considered in the study.

How to use the study?

DO NOT STOP MEDICATIONS without first consulting your doctor. If there are any serious or long term adverse effects discovered in the study, discuss the study with your doctor to ensure that proper medication management will be in place if applicable.

Who is eHealthMe?

With medical big data and proven AI/ML algorithms, eHealthMe provides a platform for everyone to run phase IV clinical trials. We study millions of patients and 5,000 more each day. Results of our real-world drug study have been referenced on 800+ peer-reviewed medical publications, including The Lancet, Mayo Clinic Proceedings, and Nature. Our analysis results are available to researchers, health care professionals, patients (testimonials), and software developers (open API).

WARNING, DISCLAIMER, USE FOR PUBLICATION

WARNING: Please DO NOT STOP MEDICATIONS without first consulting a physician since doing so could be hazardous to your health.

DISCLAIMER: All material available on eHealthMe.com is for informational purposes only, and is not a substitute for medical advice, diagnosis, or treatment provided by a qualified healthcare provider. All information is observation-only. Our phase IV clinical studies alone cannot establish cause-effect relationship. Different individuals may respond to medication in different ways. Every effort has been made to ensure that all information is accurate, up-to-date, and complete, but no guarantee is made to that effect. The use of the eHealthMe site and its content is at your own risk.

If you use this eHealthMe study on publication, please acknowledge it with a citation: study title, URL, accessed date.